These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
72 related articles for article (PubMed ID: 9375940)
21. Androgens and cardiovascular disease. Liu PY; Death AK; Handelsman DJ Endocr Rev; 2003 Jun; 24(3):313-40. PubMed ID: 12788802 [TBL] [Abstract][Full Text] [Related]
22. Exacerbation of atherosclerosis by hypertension. Potential mechanisms and clinical implications. Chobanian AV; Alexander RW Arch Intern Med; 1996 Sep; 156(17):1952-6. PubMed ID: 8823148 [TBL] [Abstract][Full Text] [Related]
23. Endothelial and Perivascular Adipose Tissue Abnormalities in Obesity-Related Vascular Dysfunction: Novel Targets for Treatment. Schinzari F; Tesauro M; Cardillo C J Cardiovasc Pharmacol; 2017 Jun; 69(6):360-368. PubMed ID: 28141700 [TBL] [Abstract][Full Text] [Related]
24. From the HOPE to the ONTARGET and the TRANSCEND studies: challenges in improving prognosis. Yusuf S Am J Cardiol; 2002 Jan; 89(2A):18A-25A; discussion 25A-26A. PubMed ID: 11835907 [TBL] [Abstract][Full Text] [Related]
25. The antiplatelet effects of nitrates: is it of clinical significance in patients with cardiovascular disease? Zhou RH; Frishman WH Cardiol Rev; 2010; 18(4):198-203. PubMed ID: 20539103 [TBL] [Abstract][Full Text] [Related]
26. Rationale and design of the LURIC study--a resource for functional genomics, pharmacogenomics and long-term prognosis of cardiovascular disease. Winkelmann BR; März W; Boehm BO; Zotz R; Hager J; Hellstern P; Senges J; Pharmacogenomics; 2001 Feb; 2(1 Suppl 1):S1-73. PubMed ID: 11258203 [TBL] [Abstract][Full Text] [Related]
27. Role of the Renin-Angiotensin-Aldosterone System and Its Pharmacological Inhibitors in Cardiovascular Diseases: Complex and Critical Issues. Borghi C; ; Rossi F; High Blood Press Cardiovasc Prev; 2015 Dec; 22(4):429-44. PubMed ID: 26403596 [TBL] [Abstract][Full Text] [Related]
31. The pathophysiology of hypertension: the importance of angiotensin II in cardiovascular remodeling. Gibbons GH Am J Hypertens; 1998 Nov; 11(11 Pt 2):177S-181S. PubMed ID: 9833876 [TBL] [Abstract][Full Text] [Related]
32. Can matrix metalloproteinase inhibitors provide a realistic therapy in cardiovascular medicine? MacFadyen RJ Curr Opin Pharmacol; 2007 Apr; 7(2):171-8. PubMed ID: 17317319 [TBL] [Abstract][Full Text] [Related]
33. Molecular mechanisms of hypertension--reactive oxygen species and antioxidants: a basic science update for the clinician. Montezano AC; Touyz RM Can J Cardiol; 2012 May; 28(3):288-95. PubMed ID: 22445098 [TBL] [Abstract][Full Text] [Related]
34. Renin-angiotensin-aldosterone system for blood pressure and electrolyte homeostasis and its involvement in hypertension, in congestive heart failure and in associated cardiovascular damage (myocardial infarction and stroke). Laragh JH J Hum Hypertens; 1995 Jun; 9(6):385-90. PubMed ID: 7473515 [TBL] [Abstract][Full Text] [Related]
35. Endothelial function as a determinant of vascular function and structure: a new therapeutic target. Gibbons GH Am J Cardiol; 1997 Mar; 79(5A):3-8. PubMed ID: 9127614 [TBL] [Abstract][Full Text] [Related]